Clinical Trial Update: Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients [Phase 3]

View source ↗

Summary

Phase 3 trial assessing 8-week Elbasvir/Grazoprevir fixed-dose therapy in treatment-naïve genotype 1b hepatitis C patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Elbasvir/Grazoprevir (elbasvir/grazoprevir)

Snippet

Sponsor: Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo | Conditions: Chronic HCV Hepatitis | Phase 3 | Status: COMPLETED